Stimulation of Coronary Collateral Growth by Granulocyte Stimulating Factor
Role of Reactive Oxygen Species

Ana Catarina R. Carrão, William M. Chilian, June Yun, Christopher Kolz, Petra Rocic, Kerstin Lehmann, Jeroen P.H.M. van den Wijngaard, Pepijn van Horssen, Jos A.E. Spaan, Vahagn Ohanyan, Yuh Fen Pung, Ivo Buschmann

Objective—The purpose of this study was to determine whether G-CSF promotes coronary collateral growth (CCG) and decipher the mechanism for this stimulation.

Methods and Results—In a rat model of repetitive episodic myocardial ischemia (RI, 40 seconds LAD occlusion every 20 minutes for 2 hours and 20 minutes, 3 times/d for 5 days) CCG was deduced from collateral-dependent flow (flow to LAD region during occlusion). After RI, G-CSF (100 µg/kg/d) increased CCG (P<0.01) (0.47±0.15) versus vehicle (0.14±0.06). Surprisingly, G-CSF treatment without RI increased CCG (0.57±0.18) equal to G-CSF+RI. We evaluated ROS by dihydroethidine (DHE) fluorescence (LV injection, 60 µg/kg, during two episodes of ischemia). DHE fluorescence was double in G-CSF+RI versus vehicle+RI (P<0.01), and even higher in G-CSF without RI (P<0.01). Interestingly, the DHE signal did not colocalize with myeloperoxidase (immunostaining, neutrophil marker) but appeared in cardiac myocytes. The study of isolated cardiac myocytes revealed the cytokine stimulates ROS which elicit production of angiogenic factors. Apocynin inhibited G-CSF effects both in vivo and in vitro.

Conclusions—G-CSF stimulates ROS production directly in cardiomyocytes, which plays a pivotal role in triggering adaptations of the heart to ischemia including growth of the coronary collaterals. (Arterioscler Thromb Vasc Biol. 2009;29:00-00.)

Key Words: G-CSF ■ coronary collateral circulation ■ ROS ■ cardiomyocytes

Granulocyte–colony stimulating factor (G-CSF) is a hormone-like glycoprotein that regulates hematopoietic cell proliferation and differentiation, and activates cells from the neutrophilic granulocyte lineage. Bacterial endotoxins, or secondary mediators induced during infections, like tumor necrosis factor-α (TNF-α), interleukin (IL)-1, and interferon-γ (IFN-γ), are major stimulators of G-CSF production in vivo. G-CSF–mediated biological actions are mediated by binding to a specific cell-surface receptor, G-CSFR, which is found on hematopoietic and nonhematopoietic cells, including myeloid progenitor cells, mature neutrophils, platelets, monocytes, endothelial cells (ECs), and adult mouse cardiomyocytes. One major function of G-CSF is to induce a multiprolonged defense against microbes, stimulating neutrophils to release proteases, DNases, and reactive oxygen species (ROS). The production of ROS may also be involved in a large number of reversible regulatory signaling processes, eg, coronary collateral development is critically dependent on redox signaling and an optimal amount of ROS. Furthermore, G-CSF was shown to ameliorate myocardial ischemic injury, by activating various signaling pathways such as Akt, ERK, Janus kinase 2 (JAK2)–signal transducer and activator of transcription 3 (STAT3; after myocardial infarction), and eNOS after ischemia/reperfusion. In this study, we projected G-CSF effects would also translate into the promotion of coronary collateral growth (CCG) under a repetitive episodic ischemia animal model, which could be mediated by the generation of ROS.

Materials and Methods
Rat Model of Collateral Growth
Male Sprague–Dawley rats (3 to 4 months old, 300 to 350 g) were used for chronic (5 days) implantation of a pneumatic occluder over the left anterior descending coronary artery (LAD), as described by Toyota et al11 to produce repetitive ischemia (RI). The RI protocol for rat consisted of 8 40-second occlusions, 1 every 20 minutes over 2 hours and 20 minutes followed by a period of “rest” for 5 hours and 40 minutes. This 8-hour cycle was repeated 3 times per day over a...
period of 5 days. Blood was collected from the animals at the beginning and end of surgical procedures for analysis of hematologic profile of groups.

**Microsphere Measurements of Myocardial and Collateral-Dependent Blood Flow**

Flow to the collateral-dependent zone was measured by neutron-activated microspheres ($5 \times 10^{10}$) labeled with Samarium or Gold. Microspheres were injected into the left ventricle (LV) over 20 seconds during LAD occlusion. Microspheres labeled with FITC were also injected with the first measurement of collateral flow. The collateral (LAD)-dependent zone was identified by the lack of fluorescent microspheres. Collateral flow was calculated as a ratio between activity (dpm/g) of the tissue samples from the LAD-dependent and normal zones.

**Echocardiographic Measurement of Cardiac Function**

To determine whether the increase in collateral-dependent blood flow led to a functional improvement, echocardiographic measurements of cardiac function were made using a VisualSonics Vevo 770 with a fundamental frequency of 20 to 35 MHz and a frame rate of 50 to 70 Hz. Left ventricular cavity dimensions were measured by M-mode echocardiography, using American Society of Echocardiography (ASE) guidelines. Measurements were made from parasternal short-axis views (at the papillary level). LV ejection fraction (EF) was calculated from images obtained during coronary occlusion (Day 5 of the RI protocol) in control rats receiving RI alone, and a group receiving RI+G-CSF.

G-CSF at a dose of 100 µg/kg/d (s.c.) was given for 5 days in the specified groups. Collateral flow was measured in the following groups (n=6/group): a sham-operated group that was instrumented but not subjected to RI; a control group/RI; G-CSF, an instrumented group but not subjected to RI; G-CSF+RI; Vehicle+RI (Vehicle=diluting solution of G-CSF; Sodium acetate 10 mmol/L pH 4.2; Sorbitol 200 mmol/L; 0.004% Tween-80); G-CSF+Apocynin (inhibitor of NADPH oxidases, 0.25 mg/mL in drinking fluid); and then with polyclonal antimyeloperoxidase (MPO, Abcam) antibody for 1 hour at room temperature. FITC secondary antibody was added, and sections were mounted in antifading agent. The slides were observed and analyzed using a fluorescence microscope.

**Cardiomyocyte Isolation**

Adult ventricular myocytes were isolated from male Sprague-Dawley rats (250 to 300 g). Rats were heparinized (300 U ip) and anesthetized with ketamine (90 mg/kg) and xylazine (10 mg/kg). Hearts were removed and retrogradely perfused for 15 minutes in Krebs-Henselekt buffer (KHB, in mmol/L: 118 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, 11 glucose) containing 5 mmol/L pyruvate and Liberase Blendzyme (0.1 mg/mL). Calcium was gradually added during the final 10 minutes of digestion to a concentration of 1.0 mmol/L. Ventricles were minced and placed in KHB containing Liberase for 10 minutes in a shaking water bath at 37°C and dispersed by trituration. The digested tissue was filtered through a 210-µm nylon mesh and the filtrate was centrifuged at 50g for 5 minutes. Pelleted cells were resuspended in DMEM and plated at a density of 50,000 rod shaped cells per well on 24-well plates precoated with laminin (1 µg/cm²). After 2 hours, wells were washed with DMEM to remove unattached cells and debris.

**Coronary Microvascular Imaging With Cryomicrotome**

One of each group of rats was prepared for coronary vascular visualization with micro-CT (n=3/group). Rat heart sectioning was performed with the imaging cryomicrotome as described previously. In brief, after sacrifice of the animals, perfusion of the rat heart was performed with the imaging cryomicrotome as described previously. Visualization with micro-CT (n=3) was conducted in n=4 as follows: Control (no treatment), G-CSF (0.05 µg/mL), G-CSF (0.1 µg/mL), G-CSF (0.3 µg/mL), G-CSF (0.3 µg/mL)+Apocynin, G-CSF (0.3 µg/mL)+MnTMPyP. DHE (5 µmol/L) was added in the last 20 minutes of treatment, and cells were observed under a fluorescent microscope.

**Inhibitors of ROS Generation**

The following metabolic inhibitors and chelators were used to inhibit ROS generation in isolated cardiomyocytes subjected to G-CSF treatment: apocynin (300 µmol/L), MnTMPyP [Mn(III)Tetrakis(1-methyl-4-pyridyl)porphyrin pentachloride] (100 µmol/L, cell-permeable superoxide dismutase mimetic). Treatments were conducted in n=4 as follows: Control (no treatment), G-CSF (0.05 µg/mL), G-CSF (0.1 µg/mL), G-CSF (0.3 µg/mL), G-CSF (0.3 µg/mL)+Apocynin, G-CSF (0.3 µg/mL)+MnTMPyP. DHE (5 µmol/L) was added in the last 20 minutes of treatment, and cells were observed under a fluorescent microscope.

**Cell Culture**

Human coronary artery endothelial cells (HCAECs) were purchased from Clonetics and were cultured at low passages (passages 3 to 8) in Clonetics EGM-2 BulletKit medium (Lonza) that contains 25% FBS, 0.2% hydrocortisone, 2% human FGF-B, 0.5% IGF-I, 0.5% ascorbic acid, 0.5% human EGF, and 0.5% GA-1000. Rat aortic smooth muscle cells were isolated from explants. Once purity was established (anti-smooth muscle α-actin immunostaining; cultures >95% positive), cells were passaged and used in early passage (up to P5). Smooth muscle cells were grown in DMEM at 37°C and 5% CO2 supplemented with 10% FBS.
To determine whether G-CSF stimulated endothelial cells and smooth muscle cells to produce superoxide, 25 000 cells were seeded in 25-mm cell culture chambers, and allowed to stabilize overnight. Varying doses of G-CSF were added (0.03, 0.3, and 3.0 µg/mL) to the media for 1 hour. During the last 20 minutes of treatment, DHE (5 µmol/L) was added and cells were observed under a fluorescent microscope.

Endothelial Tube Formation Promoted by G-CSF Cardiomycocyte Stimulation Media

Adult ventricular myocytes were isolated and plated as described above. Cardiac myocytes were stimulated with G-CSF (0.3 µg/mL) for 2 and 24 hours. This stimulation media was isolated and used to evaluate HCAEC tube formation. HCAECs were seeded on Matrigel (BD Biosciences)-coated 24-well plates according to manufacturer instructions in EGM-2 Bullet Kit medium at a density of 30 000 cells per well. Cells were allowed to attach for 24 hours before the addition of 50 ng/mL Regular Media (negative control), VEGF (positive control), 2-hour G-CSF cardiomycocyte stimulation media, 24-hour G-CSF cardiomycocyte stimulation media, 2-hour media + Apocynin (300 µmol/L), 24-hour media + Apocynin. The extent of tube formation was quantified after 24 hours by superimposing a grid (25 mm²/cube) on microscopic images, and the number of squares containing tubes were counted and averaged from 5 randomly selected fields for each well, to obtain the percentage of total field that contained tubes. Treatments were conducted in n = 4.

Data Analysis
ANOVA followed by t tests using the Bonferroni inequality was used for statistical analysis. To evaluate a functional improvement in cardiac function, a paired comparison between ejection fraction before RI protocol and at Day 5 were made, and the results are expressed as a Δchange in EF. All results are presented as mean ± SEM. A probability value of P < 0.05 was used to determine statistical significance.

Results
As shown in the hematologic profile of groups (Figure 1), G-CSF (100 µg/Kg/d) induced production of neutrophil without affecting numbers of circulating monocytic cells.

G-CSF Induces Coronary Collateral Growth
After RI, G-CSF increased CCG (P < 0.01, 0.47±0.15 versus vehicle 0.14±0.06). Surprisingly, G-CSF treatment without RI increased CCG (0.57±0.18, P < 0.01 versus vehicle) equal to G-CSF + RI (Figure 2, top). Furthermore, the increase in collateral flow induced by G-CSF translated to less of a reduction in ejection fraction (Figure 2B). Improvement in EF was noted in 1/4 vehicle + RI animals, but occurred in all (4/4) G-CSF + RI rats. The results of collateral flow and function were corroborated by the images of the coronary vasculature, where more and larger vessels were observed in the G-CSF + RI hearts (Figure 2D) versus the untreated hearts (Figure 2C).

G-CSF–Induced ROS Production
DHE fluorescence intensity was double in G-CSF with RI stimulation (P < 0.01) (81.0±2.6) versus vehicle+RI (40.6±3.8). Unexpectedly, even higher levels were found in G-CSF without RI induction (P < 0.01; 107.9±9.6; Figure 3).

To determine the cell type responsible for the increased DHE signal, myeloperoxidase (MPO, a peroxidase enzyme present in neutrophils granulocytes) immunostaining was undertaken in heart sections of the treated groups (Figure 4). Interestingly, the DHE signal did not colocalize with MPO, but appeared in cardiac myocytes.

To clearly determine whether G-CSF stimulates ROS production in cardiac myocytes, we studied isolated cardiac myocytes. The administration of different concentrations of G-CSF (0.05; 0.1; 0.3 µg/mL) revealed substantial increases in ROS production in comparison with untreated controls. Inhibition of NADPH oxidase by apocynin (300 µmol/L) or administration of the cell-permeable superoxide dismutase/catalase mimetic MnTMPyP (100 µmol/L) totally abolished the DHE signal (Figure 5). G-CSF did not increase DHE fluorescence in smooth muscle cells or endothelial cells (data...
not shown), suggesting that these cell types do not respond directly to G-CSF.

To understand whether the G-CSF stimulation of ROS in cardiac myocytes was critical for collateral growth, we additionally studied animals given apocynin and subjected to G-CSF. Apocynin prevented coronary collateral growth with or without repetitive occlusions: G-CSF + RI, 0.47 ± 0.15 versus Apocynin + G-CSF + RI, 0.09 ± 0.01 (P < 0.01); G-CSF + No RI, 0.57 ± 0.18 versus Apocynin + G-CSF + No RI, 0.09 ± 0.02 (P < 0.01, Figure 2). Moreover, DHE fluorescence intensity was completely abolished by apocynin in both groups, G-CSF + RI (81.0 ± 2.6 versus 30.6 ± 0.6, P < 0.01) and G-CSF + No RI (107.9 ± 9.6 versus 31.6 ± 9.0, P < 0.01) (Figure 3).

To clarify whether cardiomyocytes stimulated by G-CSF would produce a medium rich in angiogenic factors that would promote vascular growth, tube formation assays were undertaken. Isolated cardiomyocytes were stimulated with G-CSF for different periods of time (2 and 24 hour). This medium was then removed and used to evaluate tube formation in HCAEC cultures. As seen in Figure 6, 2-hour conditioned media from the G-CSF-treated cardiomyocytes

Figure 3. A. Fluorescence intensity of Dihydroethidium (DHE) injected into the LV (60 μg/kg) before 2 consecutive periods of repetitive ischemia. Vehicle + RI (40.6 ± 3.8); G-CSF + RI (81.0 ± 2.6); G-CSF (107.9 ± 9.6); G-CSF + Apocynin (30.6 ± 0.6); G-CSF + Apocynin (81.0 ± 9.0). B through F, Representative images of DHE fluorescence (Magnification 10×). n = 3 per group in 10 sections/heart, means ± SE, * vs vehicle, † vs G-CSF + RI; ‡ vs G-CSF, P < 0.01.

Figure 4. Immunostaining of myeloperoxidase (MPO) using a specific antibody in the rat heart. Green dots represent granulocytes in the myocardium. Original magnification is 20× for A, 10× B and C. Data shown is representative of 3 separate experiments.

Figure 5. Production of ROS by isolated cardiac myocytes revealed by DHE (5 μmol/L). A, Control, not subjected to treatment. B through D, G-CSF in different concentrations (0.05, 0.1, and 0.3 μg/mL). E, G-CSF (0.3 μg/mL) + apocynin (300 μmol/L, inhibitor NADPH oxidase) abolished DHE signal. F, G-CSF (0.3 μg/mL) + MnTMPyP (100 μmol/L, superoxide dismutase mimetic) abolished ROS production.

Figure 6. Human coronary artery endothelial cell (HCAEC) tube formation in Matrigel in response to VEGF or to conditioned media from cardiac myocytes treated with G-CSF for 2 or 24 hours. A, Percentage of area covered with tubes (n = 4 per group, means ± SE). * vs VEGF, † vs G-CSF 2 hours, ‡ vs G-CSF 24 hours, P < 0.01). B through G, Images of tube formation after addition of G-CSF cardiomyocyte stimulation medium and apocynin (300 μmol/L), as indicated.
promoted tube formation to similar values as VEGF positive control (5.6±1.9 versus 5.5±1.2, respectively). Furthermore, 24 hours of stimulation time further increases the percentage of area covered by new tubes (9.7±0.5). Apocynin clearly abolishes tube formation in both periods of time in comparison with respective groups, 2 hours (1.0±0.1) and 24 hours (0.9±0.1).

Discussion

The major observation of our study is that G-CSF stimulates coronary collateral growth with or without repetitive ischemia. We also found that the improvement in collateral flow by G-CSF was functional in that it enhanced cardiac function during a coronary occlusion. The stimulation of collateral growth in the absence of ischemia was surprising as we had predicted that G-CSF in the absence of ischemia would not initiate coronary collateral growth. However, another observation helped us resolve the dilemma of how G-CSF would initiate collateral growth in the absence of ischemia. Specifically, we found that administration of G-CSF increased ROS production in cardiac myocytes, which may mimic the well known event of enhanced ROS production during myocardial ischemia-reperfusion, suggesting that G-CSF to some extent may act as a surrogate for certain aspects of myocardial ischemia. Furthermore, we observed in isolated cardiac myocytes that G-CSF–induced ROS production is associated with the stimulation of angiogenic factors and promotion of tube formation in HCAECs, which again mimics the actions of the ischemic heart.13

Our observations and conclusions are supported by some cogent work in the literature. In support of the present study, it has been reported that G-CSF has direct and acute protective effects on myocardium against ischemia-reperfusion injury.10 It was shown that G-CSF acts directly on cardiomyocytes and induces survival signals in post-MI hearts.6 Here we show for the first time that G-CSF can promote coronary collateral growth, with or without ischemic stimuli. It was shown previously that augmentation in coronary collateral flow reveals an increase in the calibre of the collateral vessels,1 therefore the reason for the flow to increase after G-CSF treatment in comparison with RI alone is through growth of these vessels.

Intriguingly, G-CSF in the absence of repetitive ischemia also enhanced the levels of coronary collateral growth, suggesting that the cytokine mimics certain effects of ischemia. Additional results shown in our study and in the literature bear on this suggestion. We found that treatment of isolated myocytes with G-CSF stimulated the production of growth factors in a ROS-dependent manner. Ischemia-reperfusion is well known to produce a burst of ROS stimulating many adaptations of this ischemic heart including coronary collateral growth.9,14,15 Furthermore, G-CSF was found to promote neovascularization by releasing vascular endothelial growth factor (VEGF) from neutrophils and bone marrow–derived cells of hematopoietic lineage.16,17 Toyota et al11 have revealed that VEGF is required for CCG. We opine that these factors are essential for the remodeling that occurs and the promotion of coronary collateral vessels by G-CSF.

Zhu and colleagues18 have shown that G-CSF induces ROS production in peripheral blood cells and that G-CSF–induced ROS production is dependent on NADPH oxidase. It has also been demonstrated that coronary collateral development in this specific rat model of RI is critically dependent on an optimal concentration of ROS generated in the myocardium.9 Accordingly we believe that redox-dependent signaling, mediated by the stimulation of ROS by G-CSF, initiated coronary collateral development. We also emphasize that our study focused on the effects of G-CSF in a normal animal without an existing level of oxidative stress, and whether this cytokine would stimulate coronary collateral growth in a model of oxidative stress, eg, vascular disease, is unknown. We state this in view of our previous observations demonstrating that excessive amounts of ROS (oxidative stress) corrupt collateral growth but moderate amounts stimulate collateral growth.9,19 Thus, we cannot predict with certainty whether larger amounts of ROS would augment or corrupt collateral growth without knowledge of the basal redox state, or the amount of ROS that would be produced by the cytokine.

Although we initially thought that G-CSF would trigger neutrophils to the myocardium under a RI stimulus and that these neutrophils would be responsible for ROS production, we observed that G-CSF directly stimulated cardiomyocytes to generate ROS. Our studies of isolated cardiomyocytes clearly demonstrate G-CSF is acting on cardiomyocytes to produce ROS, and that this ROS generation is critical in the production of growth factors in response to G-CSF stimulation of myocytes. Furthermore, neither ECs or VSMCs responded to G-CSF with increased ROS production, suggesting that in the heart the cytokine targets cardiac myocytes. Indeed, others have suggested direct effects of G-CSF on the heart independent of granulocyte mobilization.6,20 G-CSF is also reported to have direct actions on endothelial cells, resulting in activation of p38 MAPK.21 Related to this we have recently reported a role for p38 MAPK in coronary collateral development,9 so we cannot unequivocally exclude this particular endothelial action of G-CSF in coronary collateral growth. Another possible action by which G-CSF could stimulate coronary collateral growth would be through mobilization of bone marrow stromal and progenitor cells.16,22,23 Specifically, these observations revealed that G-CSF stimulated angiogenesis and vascular growth in organ systems other than the heart and in tumors. This information may be important in the context of our previous report where multi-potent stromal cells from bone marrow amplified coronary collateral growth.24

Our results are also consistent with the conclusion that G-CSF–mediated induction of cardiomyocyte ROS is dependent on NADPH oxidase, because apocynin, an inhibitor of NADPH oxidase assembly, cancelled the effect promoted by G-CSF both in vivo and in vitro. We are also compelled to think the mechanism by which G-CSF is acting is similar to the one revealed in neutrophils by Zhu et al.,18 where G-CSF induces ROS production via NADPH oxidase. Further work is needed to verify this mechanism in cardiomyocytes.

In conclusion, we demonstrate the induction of coronary collateral growth by G-CSF, which is mediated by ROS
directly produced in cardiomyocytes. Our results offer the hypothesis that G-CSF may be acting as a surrogate for myocardial ischemia in the production of coronary collateral growth.

Acknowledgments
We thank Dr Clemens Gruber for critical reading of the manuscript and Karen Greene for administrative assistance.

Sources of Funding
This work was supported by Marie-Curie Actions (to A.C.R.C.), Boehringer Ingelheim Fonds (to A.C.R.C.), and the U.S. Public Health Service (NIH grants HL32788 and HL34286).

Disclosures
None.

References
Stimulation of Coronary Collateral Growth by Granulocyte Stimulating Factor. Role of Reactive Oxygen Species

Ana Catarina R. Carrão, William M. Chilian, June Yun, Christopher Kolz, Petra Rocic, Kerstin Lehmann, Jeroen P.H.M. van den Wijngaard, Pepijn van Horssen, Jos A.E. Spaan, Vahagn Ohanyan, Yuh Fen Pung and Ivo Buschmann

Arterioscler Thromb Vasc Biol. published online June 18, 2009;
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2009 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/early/2009/06/18/ATVBAHA.109.186445.citation

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/